{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:40:40Z","timestamp":1791247240084,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82204318"],"award-info":[{"award-number":["No. 82204318"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Youth innovation team of Liaoning Province Department of Education","award":["No. LJ222410163049"],"award-info":[{"award-number":["No. LJ222410163049"]}]},{"DOI":"10.13039\/501100018559","name":"Shenyang Young and Middle-aged Science and Technology Innovation Talent Support Program","doi-asserted-by":"publisher","award":["No. RC220389"],"award-info":[{"award-number":["No. RC220389"]}],"id":[{"id":"10.13039\/501100018559","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018617","name":"Liaoning Revitalization Talents Program","doi-asserted-by":"publisher","award":["No. XLYC2203083"],"award-info":[{"award-number":["No. XLYC2203083"]}],"id":[{"id":"10.13039\/501100018617","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Military Med Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Surface engineering has emerged as a promising strategy to enhance the performance of nanomedicines. In particular, the PEGylation levels for chemotherapy drug 7-Ethyl-10-hydroxycamptothecin (SN38) prodrug nanoparticles (NPs) play a crucial role in determining their stability, drug release kinetics, cytotoxicity, cellular uptake, in vivo pharmacokinetics, biodistribution, and antitumor efficacy. The study aims to investigate the surface engineering for chemotherapy drugs, providing new solutions for improving their in vivo delivery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We systematically evaluated the effects of different PEGylation levels on NPs (W\n                      <jats:sub>DSPE-mPEG2k<\/jats:sub>\n                      \/W\n                      <jats:sub>prodrug<\/jats:sub>\n                      ; 0%, 5%, 20%, 40%, 60%, 80%, 100%, 150%, and 200% NPs) incorporated on SN38 prodrug NPs via surface engineering. Drug release was measured using high-performance liquid chromatography (HPLC), while cytotoxicity was assessed via the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Cellular uptake was accurately quantified using liquid chromatography\u2013mass spectrometry (LC\u2013MS). The in vivo pharmacokinetics of the NPs were evaluated in Sprague\u2013Dawley rats, and the biodistribution and antitumor efficacy were assessed using a CT26 colon tumor-bearing BALB\/c mice model. Additionally, we examined intestinal toxicity to evaluate the safety profile.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All the different PEGylation levels of SN38 prodrug NPs exhibited high drug loading (&gt;\u200925%) but distinct behaviors depending on the PEGylation level. Low PEGylation (20%) led to poor colloidal stability, reduced cellular uptake, and rapid clearance by the mononuclear phagocyte system (MPS), resulting in unfavorable pharmacokinetics. Moderate PEGylation (80%) improved in vitro stability and uptake but remained insufficient to prevent rapid clearance in vivo. In contrast, high PEGylation (150%) significantly enhanced pharmacokinetic profiles, prolonged circulation, and increased tumor accumulation. The 150% NPs also showed superior antitumor efficacy without triggering anti-polyethylene glycol (PEG) immune responses or accelerated blood clearance (ABC) effects. Although high PEGylation slightly reduced cellular uptake, it conferred essential stability for systemic delivery, improving in vivo therapeutic outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The high PEGylation (150% NPs) exhibited the best antitumor effect and the lowest degree of intestinal toxicity. Our findings underscore the critical impact of PEGylation level on enhancing the performance and safety of SN38 prodrug NPs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40779-025-00648-6","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T02:43:45Z","timestamp":1758509025000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Dual character of surface engineering on SN38 prodrug nano-assemblies: divergent effects on in vitro and in vivo behavior"],"prefix":"10.1016","volume":"12","author":[{"given":"Ya-Qiao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Yu","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao-Yuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Zhong","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Xiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Xuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Fan","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Wen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-Bao","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Hui","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong-Gui","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7986-5434","authenticated-orcid":false,"given":"Bing-Jun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","published-online":{"date-parts":[[2025,9,22]]},"reference":[{"issue":"1","key":"648_CR1","doi-asserted-by":"publisher","first-page":"352","DOI":"10.21037\/jgo-22-632","volume":"14","author":"C M\u00f6hring","year":"2023","unstructured":"M\u00f6hring C, Graffe FJF, Bartels A, Sadeghlar F, Zhou T, Mahn R, et al. Second-line and third-line therapy with nanoliposomal irinotecan (nal-IRI) in pancreatic cancer: a single-center experience and review of literature. J Gastrointest Oncol. 2023;14(1):352.","journal-title":"J Gastrointest Oncol"},{"issue":"7\u20138","key":"648_CR2","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/0959-8049(95)00212-2","volume":"31","author":"J Armand","year":"1995","unstructured":"Armand J, Ducreux M, Mahjoubi M, Abigerges D, Bugat R, Chabot G, et al. CPT-11 (irinotecan) in the treatment of colorectal cancer. Eur J Cancer. 1995;31(7\u20138):1283\u20137.","journal-title":"Eur J Cancer"},{"issue":"16","key":"648_CR3","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1200\/JCO.2008.20.6300","volume":"27","author":"I Federico","year":"2009","unstructured":"Federico I, Deanna LK, Erin S, Eileen M, Jacqueline D, Mary R, et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol. 2009;27(16):2604\u201314.","journal-title":"J Clin Oncol"},{"issue":"1","key":"648_CR4","first-page":"54","volume":"2","author":"GT Li","year":"2023","unstructured":"Li GT, Jin QH, Xia FL, Fu SW, Zhang XB, Xiao HY, et al. Smart stimuli-responsive carrier-free nanoassembly of SN38 prodrug as efficient chemotherapeutic nanomedicine. Acta Mater Med. 2023;2(1):54\u201363.","journal-title":"Acta Mater Med"},{"issue":"2","key":"648_CR5","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/oxfordjournals.annonc.a059109","volume":"6","author":"GG Chabot","year":"1995","unstructured":"Chabot GG, Abigerges D, Catimel G, Culine S, de Forni M, Extra JM, et al. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol. 1995;6(2):141\u201351.","journal-title":"Ann Oncol"},{"issue":"26","key":"648_CR6","doi-asserted-by":"publisher","first-page":"4228","DOI":"10.1200\/JCO.2005.04.8496","volume":"24","author":"M Michael","year":"2006","unstructured":"Michael M, Mick T, Rod JH, Paul LM, Andrew E, Alvin DM, et al. Relationship of hepatic functional imaging to irinotecan pharmacokinetics and genetic parameters of drug elimination. J Clin Oncol. 2006;24(26):4228\u201335.","journal-title":"J Clin Oncol"},{"issue":"12","key":"648_CR7","first-page":"3089","volume":"4","author":"SM Guichard","year":"1998","unstructured":"Guichard SM, Morton CL, Krull EJ, Stewart CF, Danks MK, Potter PM. Conversion of the CPT-11 metabolite APC to SN-38 by rabbit liver carboxylesterase. Clin Cancer Res. 1998;4(12):3089\u201394.","journal-title":"Clin Cancer Res"},{"issue":"19","key":"648_CR8","doi-asserted-by":"publisher","first-page":"3843","DOI":"10.1002\/cncr.30789","volume":"123","author":"JO Allyson","year":"2017","unstructured":"Allyson JO, Alexander NS, Aditya B, Linda TV, Steven JI, Michael G, et al. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: safety and pharmacokinetics. Cancer. 2017;123(19):3843\u201354.","journal-title":"Cancer"},{"issue":"18","key":"648_CR9","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1200\/JCO.2006.10.2301","volume":"25","author":"FS Clinton","year":"2007","unstructured":"Clinton FS, John CP, Melinda AOS, Stacy LT, Charles HF, Thandranese O, et al. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan. J Clin Oncol. 2007;25(18):2594\u2013600.","journal-title":"J Clin Oncol"},{"issue":"1","key":"648_CR10","first-page":"1260","volume":"92","author":"P Renu","year":"2019","unstructured":"Renu P, Aleksandra G, Jennifer C, Andrew JB, Stefano T. Stable isotope dilution LC-HRMS assay to determine free SN-38, total SN-38, and SN-38G in a tumor xenograft model after intravenous administration of antibody-drug conjugate (sacituzumab govitecan). Anal Chem. 2019;92(1):1260\u20137.","journal-title":"Anal Chem"},{"issue":"22","key":"648_CR11","doi-asserted-by":"publisher","first-page":"5131","DOI":"10.1158\/1078-0432.CCR-15-0670","volume":"21","author":"MS Robert","year":"2015","unstructured":"Robert MS, William JM, Thomas MC, Serengulam VG, Yang W, Edmund AR, et al. Enhanced delivery of SN-38 to human tumor xenografts with an anti-trop-2-SN-38 antibody conjugate (sacituzumab govitecan). Clin Cancer Res. 2015;21(22):5131\u20138.","journal-title":"Clin Cancer Res"},{"issue":"27","key":"648_CR12","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1002\/adma.201300929","volume":"25","author":"JQ Wang","year":"2013","unstructured":"Wang JQ, Sun XR, Mao WW, Sun WL, Tang JB, Sui MH, et al. Tumor redox heterogeneity-responsive prodrug nanocapsules for cancer chemotherapy. Adv Mater. 2013;25(27):3670\u20136.","journal-title":"Adv Mater"},{"issue":"26","key":"648_CR13","doi-asserted-by":"publisher","first-page":"7650","DOI":"10.1021\/ja0256212","volume":"124","author":"X Liu","year":"2002","unstructured":"Liu X, Lynn BC, Zhang J, Song L, Bom D, Du W, et al. A versatile prodrug approach for liposomal core-loading of water-insoluble camptothecin anticancer drugs. J Am Chem Soc. 2002;124(26):7650\u20131.","journal-title":"J Am Chem Soc"},{"issue":"3","key":"648_CR14","first-page":"337","volume":"16","author":"LX Li","year":"2021","unstructured":"Li LX, Zuo SY, Dong FD, Liu T, Gao YL, Yang YX, et al. Small changes in the length of diselenide bond-containing linkages exert great influences on the antitumor activity of docetaxel homodimeric prodrug nanoassemblies. Asian J Pharm Sci. 2021;16(3):337\u201349.","journal-title":"Asian J Pharm Sci"},{"issue":"5","key":"648_CR15","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1158\/1078-0432.CCR-23-1725","volume":"30","author":"Q Wei","year":"2024","unstructured":"Wei Q, Yang T, Zhu JY, Zhang ZW, Yang L, Zhang YC, et al. Spatiotemporal quantification of HER2-targeting antibody-drug conjugate bystander activity and enhancement of solid tumor penetration. Clin Cancer Res. 2024;30(5):984\u201397.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"648_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202310633","volume":"36","author":"LX Li","year":"2024","unstructured":"Li LX, Liu T, Zuo SY, Li YQ, Zhao EW, Lu Q, et al. Satellite-type sulfur atom distribution in trithiocarbonate bond-bridged dimeric prodrug nanoassemblies: achieving both stability and activatability. Adv Mater. 2024;36(4):2310633.","journal-title":"Adv Mater"},{"issue":"3","key":"648_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101432","volume":"5","author":"SY Zuo","year":"2024","unstructured":"Zuo SY, Liu T, Li LX, Xu HZ, Guo JY, Wang Q, et al. Tetrasulfide bond boosts the anti-tumor efficacy of dimeric prodrug nanoassemblies. Cell Rep Med. 2024;5(3):101432.","journal-title":"Cell Rep Med"},{"issue":"1","key":"648_CR18","doi-asserted-by":"publisher","first-page":"7228","DOI":"10.1038\/s41467-022-35033-7","volume":"13","author":"T Liu","year":"2022","unstructured":"Liu T, Li LX, Wang S, Dong FD, Zuo SY, Song JX, et al. Hybrid chalcogen bonds in prodrug nanoassemblies provides dual redox-responsivity in the tumor microenvironment. Nat Commun. 2022;13(1):7228.","journal-title":"Nat Commun"},{"key":"648_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2024.102450","volume":"58","author":"YQ Li","year":"2024","unstructured":"Li YQ, Li LX, Hao YZ, Zhang JX, Liu CY, Zhao EW, et al. Optimizing structural design in SN38 delivery: more assembly stability and activation efficiency. Nano Today. 2024;58:102450.","journal-title":"Nano Today"},{"issue":"12","key":"648_CR20","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/nnano.2011.166","volume":"6","author":"H Cabral","year":"2011","unstructured":"Cabral H, Matsumoto Y, Mizuno K, Chen Q, Murakami M, Kimura M, et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol. 2011;6(12):815\u201323.","journal-title":"Nat Nanotechnol"},{"issue":"3","key":"648_CR21","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/s44222-023-00138-1","volume":"2","author":"H Cabral","year":"2024","unstructured":"Cabral H, Li J, Miyata K, Kataoka K. Controlling the biodistribution and clearance of nanomedicines. Nat Rev Bioeng. 2024;2(3):214\u201332.","journal-title":"Nat Rev Bioeng"},{"issue":"2","key":"648_CR22","first-page":"241","volume":"17","author":"YQ Li","year":"2022","unstructured":"Li YQ, Li LX, Jin QH, Liu T, Sun J, Wang YJ, et al. Impact of the amount of PEG on prodrug nanoassemblies for efficient cancer therapy. Asian J Pharm Sci. 2022;17(2):241\u201352.","journal-title":"Asian J Pharm Sci"},{"key":"648_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.fmre.2024.06.006","author":"BW Zhang","year":"2024","unstructured":"Zhang BW, Liu WY, Liu JR, Huang ML, Li YQ, Zhao EW, et al. Rational engineering of cholesterol-modified prodrug nanoassemblies for improving the tumor selectivity and safety of mitoxantrone. Fundam Res. 2024. https:\/\/doi.org\/10.1016\/j.fmre.2024.06.006.","journal-title":"Fundam Res"},{"issue":"5","key":"648_CR24","doi-asserted-by":"publisher","first-page":"20240074","DOI":"10.1002\/VIW.20240074","volume":"5","author":"KD Yuan","year":"2024","unstructured":"Yuan KD, Du XX, Dong L, Pan JH, Xue W. Modeling the tumor microenvironment in vitro in prostate cancer: current and future perspectives. View. 2024;5(5):20240074.","journal-title":"View"},{"issue":"45","key":"648_CR25","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abc1725","volume":"6","author":"YX Yang","year":"2020","unstructured":"Yang YX, Sun BJ, Zuo SY, Li XM, Zhou S, Li LX, et al. Trisulfide bond\u2013mediated doxorubicin dimeric prodrug nanoassemblies with high drug loading, high self-assembly stability, and high tumor selectivity. Sci Adv. 2020;6(45):eabc1725.","journal-title":"Sci Adv"},{"issue":"4","key":"648_CR26","doi-asserted-by":"publisher","first-page":"20220008","DOI":"10.1002\/EXP.20220008","volume":"2","author":"XJ Xiang","year":"2022","unstructured":"Xiang XJ, Feng X, Lu SJ, Jiang BW, Hao DY, Pei Q, et al. Indocyanine green potentiated paclitaxel nanoprodrugs for imaging and chemotherapy. Exploration. 2022;2(4):20220008.","journal-title":"Exploration"},{"issue":"1","key":"648_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11193-x","volume":"10","author":"BJ Sun","year":"2019","unstructured":"Sun BJ, Luo C, Zhang XB, Guo MR, Sun MC, Yu H, et al. Probing the impact of sulfur\/selenium\/carbon linkages on prodrug nanoassemblies for cancer therapy. Nat Commun. 2019;10(1):3211.","journal-title":"Nat Commun"},{"key":"648_CR28","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.jcis.2024.05.029","volume":"669","author":"JX Zhang","year":"2024","unstructured":"Zhang JX, Fang HK, Dai YB, Li YQ, Li LX, Zuo SY, et al. Cholesterol sulfate-mediated ion-pairing facilitates the self-nanoassembly of hydrophilic cationic mitoxantrone. J Colloid Interface Sci. 2024;669:731\u20139.","journal-title":"J Colloid Interface Sci"},{"issue":"3","key":"648_CR29","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1016\/j.apsb.2023.09.017","volume":"14","author":"S Wang","year":"2024","unstructured":"Wang S, Liu T, Huang YT, Du CY, Wang DP, Wang XY, et al. The effect of lengths of branched-chain fatty alcohols on the efficacy and safety of docetaxel-prodrug nanoassemblies. Acta Pharm Sin B. 2024;14(3):1400\u201311.","journal-title":"Acta Pharm Sin B"},{"issue":"23","key":"648_CR30","doi-asserted-by":"publisher","first-page":"23746","DOI":"10.1021\/acsnano.3c07555","volume":"17","author":"ZC Cao","year":"2023","unstructured":"Cao ZC, Liu X, Zhang WQ, Zhang KY, Pan LX, Zhu MR, et al. Biomimetic macrophage membrane-camouflaged nanoparticles induce ferroptosis by promoting mitochondrial damage in glioblastoma. ACS Nano. 2023;17(23):23746\u201360.","journal-title":"ACS Nano"},{"issue":"Pt A","key":"648_CR31","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","volume":"99","author":"JS Suk","year":"2016","unstructured":"Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. Pegylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev. 2016;99(Pt A):28\u201351.","journal-title":"Adv Drug Deliv Rev"},{"key":"648_CR32","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jconrel.2022.09.002","volume":"351","author":"S Zalba","year":"2022","unstructured":"Zalba S, Ten Hagen TL, Burgui C, Garrido MJ. Stealth nanoparticles in oncology: facing the PEG dilemma. J Control Release. 2022;351:22\u201336.","journal-title":"J Control Release"},{"issue":"8","key":"648_CR33","doi-asserted-by":"publisher","first-page":"7442","DOI":"10.1021\/acs.chemrev.1c00309","volume":"122","author":"DT Snyder","year":"2022","unstructured":"Snyder DT, Harvey SR, Wysocki VH. Surface-induced dissociation mass spectrometry as a structural biology tool. Chem Rev. 2022;122(8):7442\u201387.","journal-title":"Chem Rev"},{"issue":"8","key":"648_CR34","doi-asserted-by":"publisher","first-page":"4060","DOI":"10.1021\/nl301452x","volume":"12","author":"O Akbulut","year":"2012","unstructured":"Akbulut O, Mace CR, Martinez RV, Kumar AA, Nie Z, Patton MR, et al. Separation of nanoparticles in aqueous multiphase systems through centrifugation. Nano Lett. 2012;12(8):4060\u20134.","journal-title":"Nano Lett"},{"issue":"1","key":"648_CR35","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1039\/C6NR07353K","volume":"9","author":"L Sanchez","year":"2017","unstructured":"Sanchez L, Yi Y, Yu Y. Effect of partial PEGylation on particle uptake by macrophages. Nanoscale. 2017;9(1):288\u201397.","journal-title":"Nanoscale"},{"key":"648_CR36","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jconrel.2016.07.034","volume":"238","author":"JG Dancy","year":"2016","unstructured":"Dancy JG, Wadajkar AS, Schneider CS, Mauban JR, Goloubeva OG, Woodworth GF, et al. Non-specific binding and steric hindrance thresholds for penetration of particulate drug carriers within tumor tissue. J Control Release. 2016;238:139\u201348.","journal-title":"J Control Release"},{"issue":"16","key":"648_CR37","doi-asserted-by":"publisher","first-page":"6656","DOI":"10.1073\/pnas.1103573108","volume":"108","author":"CHJ Choi","year":"2011","unstructured":"Choi CHJ, Zuckerman JE, Webster P, Davis ME. Targeting kidney mesangium by nanoparticles of defined size. Proc Natl Acad Sci U S A. 2011;108(16):6656\u201361.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"648_CR38","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1021\/nl900031y","volume":"9","author":"SD Perrault","year":"2009","unstructured":"Perrault SD, Walkey C, Jennings T, Fischer HC, Chan WC. Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett. 2009;9(5):1909\u201315.","journal-title":"Nano Lett"},{"issue":"46","key":"648_CR39","doi-asserted-by":"publisher","first-page":"32045","DOI":"10.1021\/acsnano.4c10381","volume":"18","author":"D Cahn","year":"2024","unstructured":"Cahn D, Stern A, Buckenmeyer M, Wolf M, Duncan GA. Extracellular matrix limits nanoparticle diffusion and cellular uptake in a tissue-specific manner. ACS Nano. 2024;18(46):32045\u201355.","journal-title":"ACS Nano"},{"key":"648_CR40","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jconrel.2022.09.007","volume":"351","author":"S Jeon","year":"2022","unstructured":"Jeon S, Jun E, Chang H, Yhee JY, Koh EY, Kim Y, et al. Prediction the clinical EPR effect of nanoparticles in patient-derived xenograft models. J Control Release. 2022;351:37\u201349.","journal-title":"J Control Release"},{"issue":"11","key":"648_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202106456","volume":"34","author":"J Li","year":"2022","unstructured":"Li J, Chen C, Xia T. Understanding nanomaterial-liver interactions to facilitate the development of safer nanoapplications. Adv Mater. 2022;34(11):e2106456.","journal-title":"Adv Mater"},{"issue":"9","key":"648_CR42","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1038\/s41565-019-0499-6","volume":"14","author":"XY Jiang","year":"2019","unstructured":"Jiang XY, Du BJ, Zheng J. Glutathione-mediated biotransformation in the liver modulates nanoparticle transport. Nat Nanotechnol. 2019;14(9):874\u201382.","journal-title":"Nat Nanotechnol"},{"issue":"1","key":"648_CR43","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1038\/s41467-024-46331-7","volume":"15","author":"ZR Wang","year":"2024","unstructured":"Wang ZR, Li WP, Jiang YH, Park JH, Gonzalez KM, Wu XM, et al. Cholesterol-modified sphingomyelin chimeric lipid bilayer for improved therapeutic delivery. Nat Commun. 2024;15(1):2073.","journal-title":"Nat Commun"},{"issue":"30","key":"648_CR44","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ado8222","volume":"10","author":"GS Zhang","year":"2024","unstructured":"Zhang GS, Song DD, Ma RL, Li M, Liu BY, He ZG, et al. Artificial mucus layer formed in response to ROS for the oral treatment of inflammatory bowel disease. Sci Adv. 2024;10(30):eado8222.","journal-title":"Sci Adv"},{"key":"648_CR45","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.addr.2020.07.024","volume":"154","author":"GT Kozma","year":"2020","unstructured":"Kozma GT, Shimizu T, Ishida T, Szebeni J. Anti-PEG antibodies: properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals. Adv Drug Deliv Rev. 2020;154:163\u201375.","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"648_CR46","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1021\/acs.nanolett.0c03756","volume":"21","author":"MY Li","year":"2021","unstructured":"Li MY, Jiang S, Simon J, Pa\u00dflick D, Frey ML, Wagner M, et al. Brush conformation of polyethylene glycol determines the stealth effect of nanocarriers in the low protein adsorption regime. Nano Lett. 2021;21(4):1591\u20138.","journal-title":"Nano Lett"},{"issue":"1","key":"648_CR47","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/j.1349-7006.2008.01003.x","volume":"100","author":"MR Kano","year":"2009","unstructured":"Kano MR, Komuta Y, Iwata C, Oka M, Shirai YT, Morishita Y, et al. Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-\u03b2 receptor inhibitor on extravasation of nanoparticles from neovasculature. Cancer Sci. 2009;100(1):173\u2013806.","journal-title":"Cancer Sci"},{"issue":"1","key":"648_CR48","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13550-024-01087-5","volume":"14","author":"N Holzleitner","year":"2024","unstructured":"Holzleitner N, Fischer S, Maniyankerikalam I, Beck R, Lapa C, Wester HJ, et al. Significant reduction of activity retention in the kidneys via optimized linker sequences in radiohybrid-based minigastrin analogs. EJNMMI Res. 2024;14(1):23.","journal-title":"EJNMMI Res"},{"issue":"11","key":"648_CR49","doi-asserted-by":"publisher","first-page":"11386","DOI":"10.1021\/acsnano.8b06266","volume":"12","author":"B B\u00f8rresen","year":"2018","unstructured":"B\u00f8rresen B, Henriksen JR, Clergeaud G, J\u00f8rgensen JS, Melander F, Elema DR, et al. Theranostic imaging may vaccinate against the therapeutic benefit of long circulating PEGylated liposomes and change cargo pharmacokinetics. ACS Nano. 2018;12(11):11386\u201398.","journal-title":"ACS Nano"},{"issue":"2","key":"648_CR50","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","volume":"160","author":"YC Barenholz","year":"2012","unstructured":"Barenholz YC. Doxil\u00ae\u2014the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160(2):117\u201334.","journal-title":"J Control Release"},{"issue":"1\u20132","key":"648_CR51","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ijpharm.2013.01.012","volume":"443","author":"CL Li","year":"2013","unstructured":"Li CL, Zhao X, Wang YJ, Yang HY, Li HX, Li H, et al. Prolongation of time interval between doses could eliminate accelerated blood clearance phenomenon induced by pegylated liposomal topotecan. Int J Pharm. 2013;443(1\u20132):17\u201325.","journal-title":"Int J Pharm"},{"issue":"10","key":"648_CR52","doi-asserted-by":"publisher","first-page":"3864","DOI":"10.1002\/jps.23254","volume":"101","author":"CL Li","year":"2012","unstructured":"Li CL, Cao JN, Wang YJ, Zhao X, Deng CX, Wei N, et al. Accelerated blood clearance of pegylated liposomal topotecan: influence of polyethylene glycol grafting density and animal species. J Pharm Sci. 2012;101(10):3864\u201376.","journal-title":"J Pharm Sci"}],"container-title":["Military Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40779-025-00648-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40779-025-00648-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40779-025-00648-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T20:53:11Z","timestamp":1772830391000},"score":1,"resource":{"primary":{"URL":"https:\/\/mmrjournal.biomedcentral.com\/articles\/10.1186\/s40779-025-00648-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,22]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["648"],"URL":"https:\/\/doi.org\/10.1186\/s40779-025-00648-6","relation":{},"ISSN":["2054-9369"],"issn-type":[{"value":"2054-9369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,22]]},"assertion":[{"value":"24 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the animals used in this study were provided by the Laboratory Animal Center of Shenyang Pharmaceutical University (Shenyang, China). All the animal experiments strictly adhered to the Guidelines for the Care and Use of Laboratory Animals. This study was approved by the Institutional Animal Ethical Care Committee (IAECC) of Shenyang Pharmaceutical University (SYPU-IACUC-C2021-12-31-101).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"60"}}